caa a22 4500 397593538 CHVBK 20180308164945.0 cr unu---uuuuu 161202e199605 xx s 000 0 eng 10.1093/jac/37.suppl_A.93 doi (NATIONALLICENCE)oxford-10.1093/jac/37.suppl_A.93 Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A double-blind, randomised, parallel, multicentre study [Elektronische Daten] [L. Allegra, N. Konietzko, P. Leophonte, J. Hosie, R. Pauwels, J. N. Guyen, P. Petitpretz] In a double-blind, placebo-controlled trial, patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) were randomly allocated to oral treatment with sparfloxacin (200 mg loading dose followed by 100 mg once daily) or amoxycillin/clavulanic acid (500 mg/125 mg tds) for a total treatment duration of 7 to 14 days. Patients were evaluable if they had a FEV1/FVC ratio of less than 70% at stable state and presented with a suspected infectious exacerbation defined as increases in dyspnoea, sputum volume and sputum purulence. The primary efficacy variable was the overall success (defined as disappearance or improvement of dyspnoea and reductions in sputum volume and purulence) at end of treatment and follow-up. Overall efficacy was assessed in both the intent-to-treat (728 patients) and the evaluable (351 patients) populations. At the end of treatment and follow-up, success rates were identical for the sparfloxacin (87.3% and 78.7%) and amoxycillin-clavulanic acid (88.8% and 79.8%) treatment groups. Similar figures were found for the intent-to-treat population. The analysis of drug safety was similar for both treatment groups. The most frequently encountered pathogens were Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalts. Sparfloxacin appeared superior for bacteriological eradication of Haemophilus influenzae, and Moraxella catarrhalis. Sparfloxacin in a single daily dose appears at least as effective as amoxycillin/clavulanic acid in the treatment of patients with acute exacerbations of COPD. © 1996 The British Society for Antimicrobial Chemotherapy Articles nationallicence Allegra L. I.R.C.C.S. Ospedale Maggioze, via Francesco Sforza 35, 20122, Milan, Italy aut Konietzko N. Arztf. Inn. Med. und Pneumologie-Allergologie, Chefarzt der Ruhrlandklinik Tüschener Weg 40 4300, Essen 16, Germany aut Leophonte P. Service de Pneumologie, Hôpital Rangeuil 31052, Toulouse, France aut Hosie J. Great Western Medical, 1980 Great Western Road, Glasgow, G13 2SW, UK aut Pauwels R. Department Respiratory Diseases, University of Gent Hospital De Pintelaan 185, 9000 Gent, Belgium aut Guyen J. N. Hôpital de la Salpétrière, Laboratoire de Bactériologie 47 boulevard de l'Hôpital, 75013, Paris, France aut Petitpretz P. Service de Pneumologie, Hôpital André Mignot 177 avenue de Versailles, 78157, Le Chesnay Cedex 11, France aut Journal of Antimicrobial Chemotherapy Oxford University Press 37(1996-05), 93-104 0305-7453 37<93 1996 37 jac https://doi.org/10.1093/jac/37.suppl_A.93 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jac/37.suppl_A.93 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Allegra L. I.R.C.C.S. Ospedale Maggioze, via Francesco Sforza 35, 20122, Milan, Italy aut NATIONALLICENCE 700 1- Konietzko N. Arztf. Inn. Med. und Pneumologie-Allergologie, Chefarzt der Ruhrlandklinik Tüschener Weg 40 4300, Essen 16, Germany aut NATIONALLICENCE 700 1- Leophonte P. Service de Pneumologie, Hôpital Rangeuil 31052, Toulouse, France aut NATIONALLICENCE 700 1- Hosie J. Great Western Medical, 1980 Great Western Road, Glasgow, G13 2SW, UK aut NATIONALLICENCE 700 1- Pauwels R. Department Respiratory Diseases, University of Gent Hospital De Pintelaan 185, 9000 Gent, Belgium aut NATIONALLICENCE 700 1- Guyen J. N. Hôpital de la Salpétrière, Laboratoire de Bactériologie 47 boulevard de l'Hôpital, 75013, Paris, France aut NATIONALLICENCE 700 1- Petitpretz P. Service de Pneumologie, Hôpital André Mignot 177 avenue de Versailles, 78157, Le Chesnay Cedex 11, France aut NATIONALLICENCE 773 0- Journal of Antimicrobial Chemotherapy Oxford University Press 37(1996-05), 93-104 0305-7453 37<93 1996 37 jac Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford